公开(公告)号：US11883528B2

公开(公告)日：2024-01-30

申请号：US17893612

申请日：2022-08-23

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： David H. Ingbar ,  Timothy P. Rich ,  Robert J. Schumacher ,  Jianxun Lei ,  Maneesh Bhargava

IPC: A61K9/00 ,  A61K31/198 ,  A61P11/00

CPC classification number: A61K9/0078 ,  A61K31/198 ,  A61P11/00

Abstract: A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

公开(公告)号：US20220265775A1

公开(公告)日：2022-08-25

申请号：US17628691

申请日：2020-07-29

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： Timothy P. Rich ,  David H. Ingbar

IPC: A61K38/22 ,  A61K31/196 ,  A61K31/17 ,  A61K31/513 ,  A61K31/138 ,  A61K31/573 ,  A61K31/7076 ,  A61K38/28 ,  A61K31/343 ,  A61K31/19 ,  A61K9/00 ,  A61P11/00

Abstract: A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes an active agent effective to increase T3 concentration in the lung of the subject and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The active agent can include a deiodinase inhibitor, a thyroid hormone mimetic, or a thyroid hormone analog. In some embodiments, the composition can include an additional active agent. The compositions can be used to treat lung inflammation. In some embodiments, the compositions also can be used to treat pulmonary edema. The compositions can be administered to a subject by direct instillation to the pulmonary tract or inhalation directly to the pulmonary tract.

公开(公告)号：US20240350406A1

公开(公告)日：2024-10-24

申请号：US18539744

申请日：2023-12-14

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： David H. Ingbar ,  Timothy P. Rich ,  Robert J. Schumacher ,  Jianxun Lei ,  Maneesh Bhargava

IPC: A61K9/00 ,  A61K31/198 ,  A61P11/00

CPC classification number: A61K9/0078 ,  A61K31/198 ,  A61P11/00

Abstract: A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

公开(公告)号：US20230147865A1

公开(公告)日：2023-05-11

申请号：US17914942

申请日：2021-03-26

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： David H. Ingbar ,  Timothy P. Rich ,  Robert J. Schumacher

IPC: A61K31/198 ,  G01N33/78 ,  A61P11/00

CPC classification number: A61K31/198 ,  G01N33/78 ,  A61P11/00 ,  G01N2800/52 ,  G01N2333/575 ,  G01N2800/125

Abstract: A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

公开(公告)号：US20230050861A1

公开(公告)日：2023-02-16

申请号：US17893612

申请日：2022-08-23

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： David H. Ingbar ,  Timothy P. Rich ,  Robert J. Schumacher ,  Jianxun Lei ,  Maneesh Bhargava

IPC: A61K9/00 ,  A61P11/00 ,  A61K31/198

Abstract: A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

公开(公告)号：US11458094B2

公开(公告)日：2022-10-04

申请号：US16965095

申请日：2019-01-31

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： David H. Ingbar ,  Timothy P. Rich ,  Robert J. Schumacher ,  Jianxun Lei ,  Maneesh Bhargava

IPC: A61K9/00 ,  A61K31/198 ,  A61P11/00

Abstract: A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

公开(公告)号：US20210113462A1

公开(公告)日：2021-04-22

申请号：US16965095

申请日：2019-01-31

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： David H. Ingbar ,  Timothy P. Rich ,  Robert J. Schumacher ,  Jianxun Lei ,  Maneesh Bhargava

IPC: A61K9/00 ,  A61K31/198 ,  A61P11/00

Abstract: A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.